Molecular NeurodegenerationNeurosciencePeer-reviewed journal article
Genetic perturbations of disease risk genes in mice capture transcriptomic signatures of late-onset Alzheimer’s disease
Ravi S. PandeyiD, Leah C. GrahamiD, Asli UyariD, Christoph PreußiD, Gareth R. HowelliD, Gregory W. CarteriD
Abstract
BackgroundNew genetic and genomic resources have identified multiple genetic risk factors for late-onset Alzheimers disease (LOAD) and characterized this common dementia at the molecular level. Experimental studies in model organisms can validate these associations and elucidate the links between specific genetic factors and transcriptomic signatures. Animal models based on LOAD-associated genes can potentially connect common genetic variation with LOAD transcriptomes, thereby providing novel insights into basic biological mechanisms underlying the disease.\n\nMethodsWe performed RNA-Seq on whole brain samples from a panel of six-month-old female mice, each carrying one of the following mutations: homozygous deletions of Apoe and Clu; hemizygous deletions of Bin1 and Cd2ap; and a transgenic APOE{varepsilon}4. Similar data from a transgenic APP/PS1 model was included for comparison to early-onset variant effects. Weighted gene co-expression network analysis (WGCNA) was used to identify modules of correlated genes and each module was tested for differential expression by strain. We then compared mouse modules with human postmortem brain modules from the Accelerating Medicines Partnership for AD (AMP-AD) to determine the LOAD-related processes affected by each genetic risk factor.\n\nResultsMouse modules were significantly enriched in multiple AD-related processes, including immune response, inflammation, lipid processing, endocytosis, and synaptic cell function. WGCNA modules were significantly associated with Apoe-/-, APOE{varepsilon}4, Clu-/-, and APP/PS1 mouse models. Apoe-/-, GFAP-driven APOE{varepsilon}4, and APP/PS1 driven modules overlapped with AMP-AD inflammation and microglial modules; Clu-/- driven modules overlapped with synaptic modules; and APP/PS1 modules separately overlapped with lipid-processing and metabolism modules.\n\nConclusionsThis study of genetic mouse models provides a basis to dissect the role of AD risk genes in relevant AD pathologies. We determined that different genetic perturbations affect different molecular mechanisms comprising AD, and mapped specific effects to each risk gene. Our approach provides a platform for further exploration into the causes and progression of AD by assessing animal models at different ages and/or with different combinations of LOAD risk variants.
- organism: mouse
- assay: bulk RNA-seq
- research focus: differential expression
- approach: statistical model
- Citations
- 37
- FWCI
- 3.26
- Field percentile
- top 7%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In vivo validation of late-onset Alzheimer's disease genetic risk factors
Michael Sasner, Christoph Preuß, … Gregory W. Carter·Alzheimer s & DementiaPeer-reviewed·Apr 30, 2024
- Novel Alzheimer risk genes determine the microglia response to amyloid-β but not to TAU pathology
Annerieke S. R. Sierksma, Ashley Lu, … Mark W. E. J. Fiers·EMBO Molecular MedicinePeer-reviewed·Jan 17, 2020
- A novel systems biology approach to evaluate mouse models of late-onset Alzheimer’s disease
Christoph Preuß, Ravi S. Pandey, … Gregory W. Carter·Molecular NeurodegenerationPeer-reviewed·Nov 10, 2020
- Cross-species comparative hippocampal transcriptomics in Alzheimer's disease
Marco Antônio De Bastiani, Bruna Bellaver, … Eduardo Rigon Zimmer·iSciencePeer-reviewed·Dec 7, 2023
- Systems genetics identifies modifiers of Alzheimer’s disease risk and resilience
Sarah M. Neuner, Timothy J. Hohman, … Catherine Cook Kaczorowski·bioRxiv·Nov 27, 2017
- Genetic variability in response to Aβ deposition influences Alzheimer’s risk
Dervis A. M. Salih, Sevinç Bayram, … Valentina Escott‐Price·bioRxiv·Oct 8, 2018